RU2020127876A - Применение каннабиноидов в лечении эпилепсии - Google Patents
Применение каннабиноидов в лечении эпилепсии Download PDFInfo
- Publication number
- RU2020127876A RU2020127876A RU2020127876A RU2020127876A RU2020127876A RU 2020127876 A RU2020127876 A RU 2020127876A RU 2020127876 A RU2020127876 A RU 2020127876A RU 2020127876 A RU2020127876 A RU 2020127876A RU 2020127876 A RU2020127876 A RU 2020127876A
- Authority
- RU
- Russia
- Prior art keywords
- cbd
- use according
- treatment
- aed
- administered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/348—Cannabaceae
- A61K36/3482—Cannabis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (12)
1. Применение каннабидиола (CBD) для уменьшения судорог при эпилепсии, резистентной к лечению, где CBD вводят в комбинации с противоэпилептическим лекарственным средством (AED), которое работает как агонист к рецептору GABA.
2. Применение по п. 1, где AED, который работает посредством агонизма к рецептору GABA, представляет собой стирипентол.
3. Применение по п. 1 или 2, где CBD вводят в комбинации со стирипентолом и клобазамом.
4. Применение по любому из предшествующих пунктов, где CBD находится в форме высокоочищенного экстракта, который включает по меньшей мере 98% (мас./мас.) CBD.
5. Применение по п. 4, где высокоочищенный экстракт включает менее чем 0,15% THC.
6. Применение по п. 4, где экстракт дополнительно включает до 1% CBDV.
7. Применение по п. 1, где CBD присутствует в виде синтетического соединения.
8. Применение по любому из предшествующих пунктов, где доза CBD составляет менее 50 мг/кг/сутки.
9. Применение по любому из предшествующих пунктов, где доза CBD составляет более чем 10 мг/кг/сутки.
10. Применение по любому из предшествующих пунктов, где доза CBD составляет более чем 20 мг/кг/сутки.
11. Применение по любому из предшествующих пунктов, где эпилепсией, резистентной к лечению, является синдром Леннокса-Гасто или синдром Драве.
12. Способ лечения эпилепсии, резистентной к лечению, где CBD вводят пациенту, нуждающемуся в этом, в комбинации с противоэпилептическим средством (AED), которое работает как агонист к рецептору GABA.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1801158.5A GB2572737A (en) | 2018-01-24 | 2018-01-24 | Use of cannabinoids in the treatment of epilepsy |
| GB1801158.5 | 2018-01-24 | ||
| PCT/GB2019/050174 WO2019145700A1 (en) | 2018-01-24 | 2019-01-22 | Use of cannabinoids in the treatment of epilepsy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2020127876A3 RU2020127876A3 (ru) | 2022-02-24 |
| RU2020127876A true RU2020127876A (ru) | 2022-02-24 |
Family
ID=61283592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020127876A RU2020127876A (ru) | 2018-01-24 | 2019-01-22 | Применение каннабиноидов в лечении эпилепсии |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20200352878A1 (ru) |
| EP (1) | EP3743053B1 (ru) |
| JP (1) | JP7712079B2 (ru) |
| KR (1) | KR102785354B1 (ru) |
| CN (1) | CN111670031A (ru) |
| AU (1) | AU2019211224B2 (ru) |
| BR (1) | BR112020015018A2 (ru) |
| CA (1) | CA3089404A1 (ru) |
| DK (1) | DK3743053T3 (ru) |
| ES (1) | ES2966727T3 (ru) |
| FI (1) | FI3743053T3 (ru) |
| GB (1) | GB2572737A (ru) |
| IL (1) | IL276217B2 (ru) |
| MX (1) | MX2020007784A (ru) |
| RU (1) | RU2020127876A (ru) |
| WO (1) | WO2019145700A1 (ru) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| GB2514054A (en) | 2011-09-29 | 2014-11-12 | Gw Pharma Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2527599A (en) | 2014-06-27 | 2015-12-30 | Gw Pharma Ltd | Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2541191A (en) | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
| GB2560019A (en) | 2017-02-27 | 2018-08-29 | Gw Res Ltd | Use of cannabinoids in the treatment of leukaemia |
| GB2564383B (en) | 2017-06-23 | 2021-04-21 | Gw Res Ltd | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex |
| GB201715919D0 (en) | 2017-09-29 | 2017-11-15 | Gw Res Ltd | use of cannabinoids in the treatment of epilepsy |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
| GB201806953D0 (en) | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
| GB201910389D0 (en) | 2019-07-19 | 2019-09-04 | Gw Pharma Ltd | Novel compounds, methods for their manufacture, and uses thereof |
| GB2588576A (en) | 2019-08-27 | 2021-05-05 | Gw Res Ltd | Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease |
| GB201916849D0 (en) | 2019-11-19 | 2020-01-01 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
| GB201916846D0 (en) | 2019-11-19 | 2020-01-01 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
| GB201916977D0 (en) | 2019-11-21 | 2020-01-08 | Gw Res Ltd | Cannibidol-type cannabinoid compound |
| GB201916974D0 (en) | 2019-11-21 | 2020-01-08 | Gw Res Ltd | Cannabidol-type cannabinoid compound |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| GB2597283A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
| GB2597297A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
| GB2597282A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597299A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
| GB2597300A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
| GB2597308A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
| GB2604132A (en) * | 2021-02-25 | 2022-08-31 | Gw Res Ltd | Use of cannabidiol and clobazam in the treatment of childhood-onset epilepsy syndromes |
| US20250025482A1 (en) * | 2021-07-28 | 2025-01-23 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
| EP4507689A1 (en) | 2022-04-12 | 2025-02-19 | Shackelford Pharma Inc. | Treatment of seizure disorders |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2487712B (en) * | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| GB2530001B (en) * | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2531282A (en) * | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2531281A (en) * | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| CA2974895A1 (en) * | 2015-01-25 | 2016-07-28 | India Globalization Capital, Inc. | Composition and method for treating seizure disorders |
| GB2539472A (en) * | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2548873B (en) * | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
-
2018
- 2018-01-24 GB GB1801158.5A patent/GB2572737A/en not_active Withdrawn
-
2019
- 2019-01-22 US US16/960,665 patent/US20200352878A1/en not_active Abandoned
- 2019-01-22 DK DK19702670.1T patent/DK3743053T3/da active
- 2019-01-22 IL IL276217A patent/IL276217B2/en unknown
- 2019-01-22 BR BR112020015018-5A patent/BR112020015018A2/pt unknown
- 2019-01-22 KR KR1020207023811A patent/KR102785354B1/ko active Active
- 2019-01-22 MX MX2020007784A patent/MX2020007784A/es unknown
- 2019-01-22 ES ES19702670T patent/ES2966727T3/es active Active
- 2019-01-22 CN CN201980010033.5A patent/CN111670031A/zh active Pending
- 2019-01-22 WO PCT/GB2019/050174 patent/WO2019145700A1/en not_active Ceased
- 2019-01-22 FI FIEP19702670.1T patent/FI3743053T3/fi active
- 2019-01-22 AU AU2019211224A patent/AU2019211224B2/en active Active
- 2019-01-22 CA CA3089404A patent/CA3089404A1/en active Pending
- 2019-01-22 RU RU2020127876A patent/RU2020127876A/ru unknown
- 2019-01-22 JP JP2020540552A patent/JP7712079B2/ja active Active
- 2019-01-22 EP EP19702670.1A patent/EP3743053B1/en active Active
-
2021
- 2021-12-16 US US17/552,487 patent/US20220249396A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2966727T3 (es) | 2024-04-24 |
| US20220249396A1 (en) | 2022-08-11 |
| CN111670031A (zh) | 2020-09-15 |
| EP3743053A1 (en) | 2020-12-02 |
| DK3743053T3 (da) | 2024-01-02 |
| IL276217B1 (en) | 2025-01-01 |
| AU2019211224A1 (en) | 2020-08-13 |
| FI3743053T3 (fi) | 2023-12-14 |
| JP7712079B2 (ja) | 2025-07-23 |
| EP3743053B1 (en) | 2023-11-29 |
| BR112020015018A2 (pt) | 2021-01-19 |
| RU2020127876A3 (ru) | 2022-02-24 |
| JP2021511350A (ja) | 2021-05-06 |
| IL276217A (en) | 2020-09-30 |
| IL276217B2 (en) | 2025-05-01 |
| GB201801158D0 (en) | 2018-03-07 |
| US20200352878A1 (en) | 2020-11-12 |
| CA3089404A1 (en) | 2019-08-01 |
| KR20200112896A (ko) | 2020-10-05 |
| KR102785354B1 (ko) | 2025-03-20 |
| WO2019145700A1 (en) | 2019-08-01 |
| MX2020007784A (es) | 2020-09-18 |
| GB2572737A (en) | 2019-10-16 |
| AU2019211224B2 (en) | 2024-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020127876A (ru) | Применение каннабиноидов в лечении эпилепсии | |
| RU2020119390A (ru) | Применение каннабиноидов при лечении приступов, связанных с синдромом леннокса-гасто | |
| MX2021009646A (es) | Uso de cannabinoides en el tratamiento de epilepsia. | |
| MX2021008702A (es) | Uso de cannabinoides en el tratamiento de las comorbilidades asociadas a la epilepsia. | |
| MX379255B (es) | Uso de cannabinoides en el tratamiento de epilepsia. | |
| MX393712B (es) | Uso de cannabinoides para el tratamiento de epilepsia. | |
| Schmitz et al. | “Disease modifying nutricals” for multiple sclerosis | |
| RU2012103603A (ru) | Применение одного или комбинации фитоканнабиноидов для лечения эпилепсии | |
| MX386086B (es) | Composicion de cannabis | |
| FI3641819T3 (fi) | Kannabidiolin käyttö tuberoosisklerooosikompleksin hoitoon | |
| RU2013136378A (ru) | Применение фитоканнабиноида каннабидиола(cbd) в комбинации со стандартным противоэпилептическим стедством(saed) для лечения эпилепсии | |
| MX2023003337A (es) | Uso de cannabinoides en el tratamiento de epilepsia. | |
| FI4061344T3 (fi) | 6-hydroksikannabidioli käytettäväksi lääkkeenä | |
| PE20211065A1 (es) | Metodo para tratar la epilepsia | |
| MX386595B (es) | Métodos para el tratamiento del sobrepeso o la obesidad. | |
| MX389927B (es) | Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina. | |
| PH12017502375A1 (en) | Method of treating inflammation using natural compounds and/or diet | |
| MX2018002906A (es) | Metodos de tratamiento de trastornos del desarrollo con pipradrol. | |
| CL2012001031A1 (es) | Compuestos derivados de 2-oxo-1-pirrolidinil-imidazotiadiazol; composición farmacéutica que los comprende; útiles para el tratamiento de la epilepsia, transtornos neurológicos, entre otros. | |
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| MX377438B (es) | Administracion de tasimelteon en condiciones de ayuno. | |
| EA200970127A1 (ru) | Модулятор рецепторов глюкокортикостероидов и способы его применения | |
| MX2018000872A (es) | Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer. | |
| MX2018002298A (es) | Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos. | |
| JP2015529664A5 (ru) |